<DOC>
	<DOCNO>NCT00262327</DOCNO>
	<brief_summary>The growth metastasis solid tumor dependent angiogenesis . Endostatin , C-terminal proteolytic fragment collagen XVIII , effective endogenous angiogenesis inhibitor cancer therapy mouse . Applied clinical study solid tumor , however , recombinant human endostatin protein , difficulty large-scale production recombinant endostatin protein , cumbersome daily administration . Up , clinical application hamper matter . We herein constructed adenoviral vector ecoding human endostatin . This study test safety efficacy recombinant human endostatin adenovirus ( Ad-rhE ) treatment patient advance solid tumor .</brief_summary>
	<brief_title>Safety Efficacy Adenoviral Endostatin Treatment Advanced Solid Tumor</brief_title>
	<detailed_description>It widely recognize angiogenesis important physiological process embryonic development , wound healing , organ tissue regeneration , also play pivotal role tumor growth , tissue invasion , metastasis.1 This complex , multistep process angiogenesis involve interaction tumor cell endothelial cell ( ECs ) , growth factor , extracellular matrix component . Tumors unable elicit angiogenesis exist dormant state , unable grow beyond size 1-2 mm . Angiogenesis regulate variety pro-angiogenesis anti-angiogenesis factor imbalance lead disease . The abnormal feature tumor vasculature perhaps represent imbalanced expression proangiogenic factor antiangiogenic factors.1 Antiangiogenic therapy inhibit growth genetically stable endothelial cell , tumor starve death little acquire resistance . Antiangiogenesis agent Avastin treatment cancer approve FDA US countries.2 Endostatin , 20 kDa C-terminal fragment carboxyterminus collagen XVIII , show block endothelial cell proliferation , survival , migration , part downregulating proangiogenic factor ( Ids , HIF-1a , VEGF-A , bFGF ) upregulating antiangiogenic factor ( Thrombospondin-1,2 , vasostatin , kininogen ) .4,5,6 Of endogenous antiangiogenic factor body , endostatin broad anti-cancer spectrum least toxic resistance anti-cancer drug mouse human . Endostatin first endogenous angiogenesis inhibitor introduce human clinical trial . However , therapy recombinant endostatin protein hamper shot half-life , difficulty protein production long-term storage bioactive protein . Furthermore , inhibition tumor angiogenesis long-term chronic process treatment . Gene therapy may overcome difficulty introduce human endostatin cDNA host use body endogenous factory generate highly bioactive gene product . Expression endostatin adenoviral gene transfer ( Ad-rhEndo , E10A ) generate strong systemic therapeutic effect several model solid tumor mice.7,8,9,10 Intratumoral injection E10A subcutaneous xenograft hepatocellular carcinoma BEL-7402 , nasopharyngeal carcinoma CNE-2 , Tongue cancer Tca8113 nude mouse demonstrate significant tumor growth inhibition reduce angiogenesis tumor . No toxic effect E10A administration pharmacology study identify . On base promise preclinical result solid tumor , undertook dose-escalation phase I trial E10A treatment patient advance solid tumor .</detailed_description>
	<mesh_term>Endostatins</mesh_term>
	<criteria>Age 18 65 year ; Genders eligible study : ; Histologic diagnosis solid malignancy ; Performance status 0 1 ; Tumor amenable standard curative palliative therapy ; An accessible tumor mass ; At least 4 week since prior biotherapy/chemotherapy/radiotherapy ; A life expectancy beyond 3 month ; Ability give sign informed consent . Pregnancy lactation ; Had history brain metastasis primary brain tumor ; An active , potentially severe autoimmune disease ; Serum creatinine ≥1.5mg/dl calculate creatinine clearance ＜60ml/min ; WBC count &lt; 2.0×109/L，hemoglobin &lt; 90g/L，and platelet count &lt; 100×109/L ; Total bilirubin value &lt; 2.0 time upper limit normal ( ULN ) , ALT level &lt; 2.0 time ULN , AST &lt; 2.0 time ULN ; Positive antiHIV antibody ; An active bacterial , fungal , viral infection ; Less one month since prior systemic immunosuppressive drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>antiangiogenesis</keyword>
	<keyword>endostatin</keyword>
	<keyword>adenovirus</keyword>
	<keyword>gene therapy</keyword>
	<keyword>cancer</keyword>
</DOC>